We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Groupe Crit | EU:CEN | Euronext | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.40 | 0.54% | 74.00 | 73.80 | 75.60 | 75.60 | 73.80 | 75.60 | 2,943 | 16:40:00 |
Hot Features
Premium
RNS Number:9628S
CeNeS Pharmaceuticals PLC
08 December 2003
CENES PHARMACEUTICALS PLC ("the Company")
HOLDING IN COMPANY
Following announcement by the Company on 24 November 2003, GlaxoSmithKline plc
has a notifiable interest in 13,284,508 ordinary shares of 1p each, representing
5.03% of the current issued share capital of the Company.
This holding is registered as follows:
No. of Ordinary % of issued Share
Shares Capital
SmithKline Beecham Corporation 5,789,920 2.31
Glaxo Group Limited 7,494,588 2.99
GlaxoSmithKline plc total holding 13,284,508 5.30
Further information
Neil Clark, CeNeS Pharmaceuticals plc 01223 266 466
5 December 2003
This information is provided by RNS
The company news service from the London Stock Exchange
END
HOLUVOWRORRURAA
1 Year Groupe Crit Chart |
1 Month Groupe Crit Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
